Xgene Pharmaceutical Reports Results from P-IIb Trial of XG005 for Post-Surgical Pain

Shots: The P-IIb trial is evaluating XG005 (1250mg or 750mg, BID, oral) vs PBO in patients (n=450) for managing acute pain after bunionectomy Results showed reduced pain intensity over 72hrs. post-surgery, with mild pain (<4 NRS) in high dose group vs severe pain (>7 NRS) in PBO; delayed rescue medication use of up to…

BySenior EditorJanuary 2, 2025

NEWS

ADC Therapeutics Reports Enrollment Completion in P-III (LOTIS-5) Study of Zynlonta Plus Rituximab for 2L+ Diffuse Large B-Cell Lymphoma

Shots: The patient enrollment in confirmatory P-III (LOTIS-5) study assessing Zynlonta + rituximab for treating 2L+ r/r DLBCL has been completed. Zynlonta was previously approved in 2021 under accelerated pathway for the same The study aims to convert accelerated approval & support label expansion to 2L+ with rituximab. Part 1 enrolled 20 patients for…

BySenior EditorJanuary 1, 2025

VIEWPOINTS

Macrophage Checkpoint Therapy: Roy Maute from Pheast Therapeutics in a Riveting Conversation with PharmaShots

Shots: Recently Pheast Therapeutics shared the preclinical data for PHST001, an anti-CD24 macrophage checkpoint inhibitor at the 20th Annual PEGS Boston Summit Today, at PharmaShots, we had a dialogue exchange with Roy Maute, Cofounder and CEO of Pheast Therapeutics Pheast Therapeutics currently plans to initiate a clinical trial in H1’25 Saurabh: Can you walk me…

BySaurabh ChaubeyJune 26, 2024

VIEWPOINTS

Funds Raised: David Domzalski Discusses the Closing of VYNE Therapeutics’ Private Placement

Shots: David Domzalski, President & Chief Executive Officer at VYNE Therapeutics, in an invigorating conversation with PharmaShots The PIPE transaction generated $88M ensuring a steady cash flow through the end of 2025 and multiple anticipated clinical catalysts across VYNE’s BET inhibitor platform David believes the financing will be instrumental in the advancement of VYN201, into…

BySaurabh ChaubeyJanuary 29, 2024

INSIGHTS+

PharmaShots’ Key Highlights of Fourth Quarter 2023

Shots: The Fourth quarter of 2023 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. Starting with the latest acquisitions, BMS acquired Mirati Therapeutics for ~$5.8B and AbbVie acquired ImmunoGen for $10.1B The Fourth quarter of the year also showcases multiple clinical trial results from Regeneron’s Two-Year…

BySenior EditorJanuary 16, 2024

VIEWPOINTS

A stirring conversation between Catherine Liao and PharmaShots on SphygmoCor Technology

Shots: Catherine Liao, Chief Strategy Officer of CardieX, discusses the recent partnership between CardieX’s subsidiary ATCOR and Datacubed Health Catherine delves deep into the growing dependence on decentralized clinical trials in the healthcare community and cites a few challenges in the study that come with it Catherine stresses the potential of SphygmoCor technology while discussing…

BySaurabh ChaubeyOctober 30, 2023

VIEWPOINTS

The US FDA OTC Approval of Topical Gel for Erectile Dysfunction: Insights from Ken James

Shots: Ken gave a brief overview of the OTC marketing approval of Eroxon (MED3000) by the US FDA. He also talked about Eroxon’s mechanism of action and how it helps to treat erectile dysfunction Later, he discussed the study design and results obtained from the clinical trial based on which the approval was granted. In…

BySenior EditorSeptember 21, 2023

VIEWPOINTS

Dr. Mourad Farouk Rezk, Head of Global Medical & Development Biogen Biosimilars Shares Insights on BLA Acceptance for BIIB800

Shots: Dr. Mourad spoke about the acceptance of aBLA for BIIB800, a Tocilizumab biosimilar candidate for several autoimmune diseases, including rheumatoid arthritis He briefed about the study design and results from the P-III trial which supported the BLA filing This interview focuses on Biogen's notable progress in addressing challenging immunologic conditions, offering potential solutions to…

BySenior EditorJuly 10, 2023

THOUGHTSPOT

Intelligent Automation in Pharmaceutical Industry (AI & ML)

Shots: Driven by the influx of life-changing innovations and technological advances, the pharmaceutical industry is forging ahead at a momentous pace. With the impelling Pharma 4.0, automation has now been embedded in various aspects of current business practices Delving deeply into the importance of automation, primarily focusing on AI & ML, PharmaShots unveils its eight-step…

BySaurabh ChaubeyJune 6, 2023

THOUGHTSPOT

4 Steps To Ensure Clinical Trial Compliance

When performing research studies, clinical trial compliance plays a vital part in ensuring the safety and effectiveness of the research. It means adhering to ethical and regulatory requirements established by governing bodies that guarantee the well-being of study participants and the legitimacy of study results. Sponsors, investigators, and study sites could face considerable legal and…

ByAdrian WallaceApril 26, 2023

Xgene Pharmaceutical Reports Results from P-IIb Trial of XG005 for Post-Surgical Pain

ADC Therapeutics Reports Enrollment Completion in P-III (LOTIS-5) Study of Zynlonta Plus Rituximab for 2L+ Diffuse Large B-Cell Lymphoma

Macrophage Checkpoint Therapy: Roy Maute from Pheast Therapeutics in a Riveting Conversation with PharmaShots

Funds Raised: David Domzalski Discusses the Closing of VYNE Therapeutics’ Private Placement

PharmaShots’ Key Highlights of Fourth Quarter 2023

A stirring conversation between Catherine Liao and PharmaShots on SphygmoCor Technology

The US FDA OTC Approval of Topical Gel for Erectile Dysfunction: Insights from Ken James

Dr. Mourad Farouk Rezk, Head of Global Medical & Development Biogen Biosimilars Shares Insights on BLA Acceptance for BIIB800

Intelligent Automation in Pharmaceutical Industry (AI & ML)

4 Steps To Ensure Clinical Trial Compliance

Contact US

FOLLOW US